Cerus Stock Price, News & Analysis

Cerus Corporation (CERS) has secured regulatory approvals from French ANSM and Swiss Swissmedic for its INT200, a next-generation LED-based illumination device for the INTERCEPT Blood System. The INT200 features significant improvements over its predecessor, including a vertical configuration that allows three devices to fit in the space of one INT100, touch screen navigation, improved tray design, intelligent scanning, and custom reporting. This follows the CE Mark authorization received in March. Both France and Switzerland have been using INTERCEPT Blood System for all platelet components since 2018 and 2011 respectively. Cerus plans to convert its EMEA INT100 installed base to INT200s over the next three years and aims to submit a PMA to the FDA during 2026.

Cerus Corporation (CERS) reported strong Q1 2025 financial results with total revenue of $48.9M, up 13% year-over-year. Product revenue reached $43.2M, also up 13%, while government contract revenue was $5.6M. The company's INTERCEPT Fibrinogen Complex (IFC) showed significant growth with Q1 revenue of $3.0M compared to $1.9M in the prior year. Notable achievements include receiving CE Mark for INT200, their next-generation LED-based illumination device, and submitting an updated CE Mark application for the INTERCEPT red blood cell system. The company reported a net loss of $7.7M ($0.04 per share), improved from $9.7M loss year-over-year. With $80.9M in cash and equivalents, Cerus maintains its 2025 product revenue guidance of $194-200M. North American revenue grew 22%, while EMEA declined 4% due to forex impact.

Cerus (CERS) has scheduled the release of its first quarter 2025 financial results for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss financial performance and provide business updates.

Management will present detailed financial results and offer a general business overview and outlook during the call. A replay of the event will be accessible on Cerus' website until May 22, 2025.

Cerus (CERS) has received CE mark approval for its next-generation LED-based illumination device (INT200) for the INTERCEPT Blood System for platelets and plasma under the EU Medical Device Regulation (MDR). This approval enables Cerus to market the INT200 throughout the European Union and regions recognizing CE mark certification.

The INT200 represents a significant upgrade featuring enhanced physical design and new software interface while maintaining compatibility with existing processing sets. This approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework, following the 2023 CE mark approvals of INTERCEPT processing sets.

The CE mark represents the first regulatory approval for Cerus' next-generation illuminator, with additional regulatory submissions planned over coming years. The INT200 will serve as the foundation for geographic expansion and future growth of the INTERCEPT business.

Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.

Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.

The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.

Cerus (Nasdaq: CERS) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team is scheduled to present at a fireside chat on Wednesday, March 5, at 11:10 a.m. EST. The presentation will be accessible through a live webcast, with a replay available for 90 days following the event.

Cerus (Nasdaq: CERS) has scheduled the release of its fourth quarter and full-year 2024 financial results for Thursday, February 20, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day, featuring management discussions on financial results, business overview, and outlook.

Interested participants can access the webcast and presentation slides through Cerus' Investor Relations webpage at http://ir.cerus.com. While early joining is encouraged (10 minutes prior), it's not mandatory. A replay of the event will be available on the company's website approximately three hours after the call until March 6, 2025.

Cerus (CERS) reported preliminary full-year 2024 product revenue of $180.3 million, exceeding their guidance of $177-$179 million and marking a 15% increase over 2023. The growth was driven by strong performance in their INTERCEPT platelet franchise and IFC business, which grew 42% to reach $9.2 million in revenue.

For 2025, Cerus projects product revenue between $194-$200 million, representing 8-11% year-over-year growth. IFC revenue is expected to range from $12-$15 million. The company anticipates Q1 2025 product revenue growth of 10-15% compared to Q1 2024. Future initiatives include the planned LED Illuminator launch in Europe and geographic expansion efforts.

Cerus (Nasdaq: CERS) has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel conference presentation will be available online, with a replay accessible on the company's website following the event.